Literature DB >> 17186005

Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population.

W M Cai1, B Chen, W X Zhang.   

Abstract

To study the frequency of CYP2D6(*)10 and (*)14 alleles in a healthy Chinese population, and the influence of these two alleles on the metabolic activity of CYP2D6. CYP2D6(*)10 and (*)14 genotypes of 295 healthy Chinese subjects were determined using a tetra-primer method and allele-specific amplification. CYP2D6 phenotypes of 131 subjects were determined using dextramethorphan as probe drug. There were 10 subjects with a (*)14 allele, including one homozygous for (*)14. The gene frequency of (*)10 and (*)14 alleles were 55.8 and 1.8%, respectively. The metabolic ratio (MR) of dextramethorphan in 131 subjects was 0.032+/-0.106. The MR of (*)1/(*)1, (*)1/(*)10, (*)10/(*)10, (*)1/(*)14, (*)10/(*)14, and (*)14/(*)14 groups were 0.007+/-0.012, 0.009+/-0.010, 0.042+/-0.029, 0.093, 0.11, and 1.186, respectively. The MR of subjects with (*)14 allele was higher than those of (*)1/(*)1, (*)1/(*)10, or (*)10/(*)10 groups (P<0.001). The CYP2D6(*)10 and (*)14 alleles have substantial impact on the metabolic activity of CYP2D6, and the CYP2D6(*)14 allele may be the cause of the poor metabolizer phenotype in Chinese subjects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17186005     DOI: 10.1038/sj.clpt.6100015

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Allelic and genotype frequencies of catechol-O-methyltransferase (Val158Met) and CYP2D6*10 (Pro34Ser) single nucleotide polymorphisms in the Philippines.

Authors:  Michael O Baclig; Rey Z Predicala; Cynthia A Mapua; Jingky P Lozano-Kühne; Maria Luisa G Daroy; Filipinas F Natividad; Francis O Javier
Journal:  Int J Mol Epidemiol Genet       Date:  2012-05-15

2.  Pharmacokinetics of dimemorfan phosphate tablets in healthy Chinese volunteers.

Authors:  Yali Shen; Zhu Luo; Qin Yu; Ying Wang; Jin Xiang; Jia Miao
Journal:  Eur J Clin Pharmacol       Date:  2017-02-28       Impact factor: 2.953

3.  Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis.

Authors:  Qi Pei; Lu Huang; Jie Huang; Jing-Kai Gu; Yun Kuang; Xiao-Cong Zuo; Jun-Jie Ding; Hong-Yi Tan; Cheng-Xian Guo; Shi-Kun Liu; Guo-Ping Yang
Journal:  Acta Pharmacol Sin       Date:  2016-09-26       Impact factor: 6.150

Review 4.  CYP2D6 and tamoxifen: DNA matters in breast cancer.

Authors:  Janelle M Hoskins; Lisa A Carey; Howard L McLeod
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

Review 5.  Individualized medicine enabled by genomics in Saudi Arabia.

Authors:  Muhammad Abu-Elmagd; Mourad Assidi; Hans-Juergen Schulten; Ashraf Dallol; Peter Pushparaj; Farid Ahmed; Stephen W Scherer; Mohammed Al-Qahtani
Journal:  BMC Med Genomics       Date:  2015-01-15       Impact factor: 3.063

6.  Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.

Authors:  Se-Hyung Kim; Ji-Young Byeon; Young-Hoon Kim; Choong-Min Lee; Yun Jeong Lee; Choon-Gon Jang; Seok-Yong Lee
Journal:  Sci Rep       Date:  2018-08-17       Impact factor: 4.379

Review 7.  Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.

Authors:  Mujeeb U Shad
Journal:  Behav Sci (Basel)       Date:  2021-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.